TACR1-IN-1
TACR1-IN-1 is a TACR1 inhibitor. TACR1-IN-1 attenuates Substance P-driven ERK phosphorylation and downstream malignant programs. TACR1-IN-1 reduces PGP9.5-positive tumor innervation in orthotopic PDAC models. TACR1-IN-1 increases antigen presentation and immune chemokine-related transcript expression under Substance P treatment conditions. TACR1-IN-1 reverses Substance P-associated reduction in Gemcitabine (HY-17026) sensitivity. TACR1-IN-1 can be used for research on pancreatic ductal adenocarcinoma.
For research use only. We do not sell to patients.
- CAS No.: 901730-21-0
- Formula: C23H24FN3O3
- Molecular Weight:409.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
NK1R |
In Vitro
TACR1-IN-1 (Compound C547) binds to TACR1 in MIA PaCa-2 cells, as confirmed by the change in thermal stability in CETSA[1].
TACR1-IN-1 (72 h) shows a stronger selective inhibitory effect on the viability of MIA PaCa-2 cells with high TACR1 expression than on PANC-1 cells with low TACR1 expression[1].
TACR1-IN-1 (0-72 h) preferentially inhibits Substance P (HY-P0201)-driven growth in MIA PaCa-2 cells with high TACR1 expression[1].
TACR1-IN-1 (0-48 h) inhibits Substance P-induced migration of MIA PaCa-2 cells[1].
TACR1-IN-1 (48 h) attenuates Substance P-driven ERK activation in MIA PaCa-2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MIA PaCa-2; PANC-1
-
Concentration:1 μM (SP); increasing concentrations (C547)
-
Incubation Time:72 h
-
Result:Showed the strongest inhibitory activity in MIA PaCa-2 cells among the tested compounds.
Showed limited effects in TACR1-low PANC-1 cells even at higher concentrations.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 6-8 weeks)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; three times per week; starting on day 5 after tumor implantation
-
Result:Reduced orthotopic pancreatic tumor growth and decreased tumor weight at end point.
Did not show an obvious reduction in body weight compared to vehicle-treated controls.
Did not reveal overt morphological abnormalities in major organs.
Reduced PGP9.5-positive nerve fiber density in tumor tissues compared with vehicle treatment.
Upregulated Cd3, Cd8a, Gzmb, Prf1, and other immune-activated genes in KPPC tumors.
Chemical Information
-
CAS No. 901730-21-0
-
Molecular Weight 409.45
-
Formula C23H24FN3O3
-
SMILES
FC1=CC=C(N2CCN(C(COC3=CC(N(CC)C4=CC=CC=C43)=O)=O)CC2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)